Graphical Abstract:

Abstract:

The possibility to target cellular senescence with natural bioactive substances open interesting
therapeutic perspective in cancer and aging. Engaging senescence response is suggested as a key
component for therapeutic intervention in the eradication of cancer. At the same time, delaying senescence
or even promote death of accumulating apoptosis-resistant senescent cells is proposed as a strategy
to prevent age related diseases. Although these two desired outcome present an intrinsic dichotomy,
there are examples of promising natural compounds that appear to satisfy all the requirements to develop senescence-
targeted health promoting nutraceuticals. Tocotrienols (T3s) and quercetin (QUE), albeit belonging to different
phytochemical classes, display similar and promising effects “in vitro” when tested in normal and cancer cells. Both compounds
have been shown to induce senescence and promote apoptosis in a multitude of cancer lines. Conversely, they display
senescence delaying activity in primary cells and rejuvenating effects in senescent cells. More recently, QUE has
been shown to display senolytic effects in some primary senescent cells, likely as a consequence of its inhibitory effects
on specific anti-apoptotic genes (i.e. PI3K and other kinases). Senolytic activity has not been tested for T3s but part of
metabolic and apoptotic pathways affected by these compounds in cancer cells overlap with those of QUE. This suggests
that the rejuvenating effects of T3s and QUE on pre-senescent and senescent primary cells might be the net results of a
senolytic activity on senescent cells and a selective survival of a sub-population of non-senescent cells in the culture. The
meaning of this hypothesis in the context of adjuvant therapy of cancer and preventive anti-aging strategies with QUE or
T3s is discussed.

Abstract:The possibility to target cellular senescence with natural bioactive substances open interesting
therapeutic perspective in cancer and aging. Engaging senescence response is suggested as a key
component for therapeutic intervention in the eradication of cancer. At the same time, delaying senescence
or even promote death of accumulating apoptosis-resistant senescent cells is proposed as a strategy
to prevent age related diseases. Although these two desired outcome present an intrinsic dichotomy,
there are examples of promising natural compounds that appear to satisfy all the requirements to develop senescence-
targeted health promoting nutraceuticals. Tocotrienols (T3s) and quercetin (QUE), albeit belonging to different
phytochemical classes, display similar and promising effects “in vitro” when tested in normal and cancer cells. Both compounds
have been shown to induce senescence and promote apoptosis in a multitude of cancer lines. Conversely, they display
senescence delaying activity in primary cells and rejuvenating effects in senescent cells. More recently, QUE has
been shown to display senolytic effects in some primary senescent cells, likely as a consequence of its inhibitory effects
on specific anti-apoptotic genes (i.e. PI3K and other kinases). Senolytic activity has not been tested for T3s but part of
metabolic and apoptotic pathways affected by these compounds in cancer cells overlap with those of QUE. This suggests
that the rejuvenating effects of T3s and QUE on pre-senescent and senescent primary cells might be the net results of a
senolytic activity on senescent cells and a selective survival of a sub-population of non-senescent cells in the culture. The
meaning of this hypothesis in the context of adjuvant therapy of cancer and preventive anti-aging strategies with QUE or
T3s is discussed.